Document is current
Any future updates will be listed below
-
Authors
Didcote, Lyndsay https://orcid.org/0009-0006-5516-0126
Vitoratou, Silia https://orcid.org/0000-0003-1209-8167
Al-Chalabi, Ammar https://orcid.org/0000-0002-4924-7712
Goldstein, Laura H. https://orcid.org/0000-0001-9387-3035
-
Funding
Funding for this research was provided by:
Motor Neurone Disease Association (Goldstein/Oct17/892-792)
- License Information
-
More Information
Article History
Received: 25 September 2024
Revised: 1 December 2024
Accepted: 2 December 2024
First Online: 15 January 2025
Declarations
:
: AAC reports consultancies or advisory boards for Amylyx, Apellis, Biogen, Brainstorm, Cytokinetics, GenieUs, GSK, Lilly, Mitsubishi Tanabe Pharma, Novartis, OrionPharma, Quralis, Sano, Sanofi, and Wave Pharmaceuticals. AAC reports the following patent: Use of CSF-Neurofilament determinations and CSF-Neurofilament thresholds of prognostic and stratification value with regards to response to therapy in neuromuscular and neurodegenerative diseases. The other authors have no conflicts of interest to declare.
: The London-Dulwich Research Ethics Committee and the Health Research Authority (Reference 18/LO/1257) gave ethical approval for this study to be conducted. The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.
